

related recombinant allergens which discriminate with 100% specificity between ABPA and allergic sensitization to *A. fumigatus*.--

--15. (NEW) The method according to claim 14, wherein the allergen is derived from *A. fumigatus*.--

--16. (NEW) The method according to claim 15, wherein the allergen corresponds to a non-secreted protein from *A. fumigatus*.--

--17. (NEW) The method according to claim 14, wherein an in vitro immunoassay is carried out on a fluid sample from the individual for the determination of the level of antibodies directed towards said recombinant allergens.--

--18. (NEW) The method according to claim 17, wherein antibodies of the IgE class or IgE class, or subclasses thereof, are determined.--

--19. (NEW) The method according to claim 17, wherein antibodies of the IgE class are determined.--

--20. (NEW) The method according to claim 14, wherein an in vivo test is carried out in the individual.--

--21. (NEW) The method according to claim 20, wherein the test is a skin test involving placing said one or more ABPA-related recombinant allergens in the skin of the patient.--

--22. (NEW) The method according to claim 20, wherein antibodies of the IgE class or IgE class, or subclasses thereof, are determined.--

--23. (NEW) The method according to claim 20, wherein antibodies of the IgE class are determined.--